A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse
Clinical trial NCT06643585 · RECRUITING
Trial details
- NCT number
- NCT06643585
- Sponsor
- Prof. Wolfgang Janni
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-22
- Primary completion
- 2032-04-22
- Enrollment
- 180
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.